AzTrials
AzTrials

DementiaNCT02426398

Developing a New EEG Method for the Early Diagnosis of Dementia

An observational study of Dementia, run by Sheffield Teaching Hospitals NHS Foundation Trust at 1 site in United Kingdom.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This is a non-invasive study investigating whether EEG, which is used in routine clinical care can be useful in diagnosing dementia. Novel in house developed software will analyse EEG data for this purpose from people with Alzheimer's disease and healthy volunteers. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Dementia
How many people
128 participants
Where
1 siteUnited Kingdom
Study dates
19 Nov 2014to 1 Jun 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Clinical diagnosis of possible or probable AD (according to revised diagnostic criteria (McKhann et al., 2011, Dubois et al., 2007)

Who may be able to join

  • Clinical diagnosis of possible or probable AD (according to revised diagnostic criteria (McKhann et al., 2011, Dubois et al., 2007)

Who cannot join

  • Significant vascular change on neuro-imaging (Fazekas grading of white matter change >2) (Fazekas et al., 2002).
  • Clinical history of stroke, Parkinsonism, epilepsy or other neurological disorder. (e.g. severe auditory, visual, language or motor impairment)
  • Moderate to severe dementia (defined by research team but we wouldn't expect those with a mini mental state exam [MMSE] ≤ 18 to be able to participate)
  • Severe current mental health disorder (depression, psychosis).
  • Patients on sedating or antiepileptic medication

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Daniel Blackburn, MBChB, PhD contact

01142222267

d.blackburn@shef.ac.uk

Jodie Keyworth contact

j.keyworth@shef.ac.uk

United Kingdom1 site, 1 recruiting
  • Sheffield Teaching Hospitals NHS Trust

    Sheffield, S Yorks, S10 2HQ

    Recruiting

Other trials in United Kingdom

About this study

Official title: Developing a New EEG Method for the Early Diagnosis of Dementia. Using Novel EEG Analyses to Create a Diagnostic Test and Biomarker for Use With People With Dementia

This is a non-invasive study investigating whether EEG, which is used in routine clinical care can be useful in diagnosing dementia. Novel in house developed software will analyse EEG data for this purpose from people with Alzheimer's disease and healthy volunteers.

Read the detailed description

Participant recruitment

15 people with early AD will be recruited from the Sheffield Teaching Hospital and Sheffield Health and Social Care NHS Trusts memory clinics. The STH clinic is neurology led and sees working age (<65 years old) patients while the SHSC clinic sees an older (>65 years old) population. Over 1300 new assessments are conducted every year. Approximately 65-70% are diagnosed with dementia.

Investigators will choose patients with typical neuropsychological profiles of AD. All patients will have previously been recruited to the Virtual Physiological Human: Dementia Research enabled by IT. VPH-DARE@IT is recruiting 30-40 participants in each of the three following groups (mild AD, MCI and normal controls) and thus our participants will be drawn from this group and all will have pre-existing high-resolution 3D structural and volumetric assessment plus resting-state fMRI scans. This resting-state fMRI data will be analysed to examine the DMN, allowing us to directly compare measures of brain-connectivity between EEG and fMRI and contrast the discriminatory ability of the two methodologies.

10 healthy controls will be aged matched and recruited either from Neurology clinics or be spouses of study participants. The investigators will endeavour to recruit normal controls who have undergone fMRI as part of the academic neuroradiology departments control population for VPH-DARE@IT and other studies.

People with AD and 10 healthy controls will have a repeat EEG to assess the reproducibility and robustness of the EEG measures.

EEG is normally very well tolerated and as listed in the background has been used in many people with dementia. The Clinical Neurophysiology department is very experienced in undertaking EEG in all patient populations from neonates to the very elderly.

Consent Participants will be identified by the clinicians working in the memory clinic or through posters in memory clinic and at other University sites to attract normal volunteers. A Participation Information Sheet (PIS) will be given to them either directly or via post. Participants will have sufficient time to read the PIS and be able to ask questions. The PIS will inform the participant of the benefits and potential risks involved in taking part in this study. They will be made aware of the possibility that incidental changes are rarely detected. If this is seen they would be informed and we would arrange appropriate management. The person will be consented when they come in for the EEG recordings. Investigators will explain to all participants that they will be able to leave the study at any time including during the EEG recording and in those that we plan to repeat the EEG can decline the 2nd test. The Clinical Department of Neurophysiology has experience in performing EEG in all ages including those with dementia and cognitive impairment. The person with dementia's care-giver or family member can come to the department and be in the room for the entire time the EEG recording takes place.

Methodology EEG data capture

  • Participants will attend the department of clinical neurophysiology and a member of the research team will take consent. Two experienced EEG technicians will place the electrodes and explain the procedure. We will record resting state EEG. Participants will be told to lie still with eyes closed. It will be explained that although their eyes are closed they must remain awake. Participants will be continuously monitored and if they become drowsy will be re-stimulated and the time of drowsiness will be recorded. This instruction and monitoring is the same as that used in previous EEG and fMRI studies looking at resting state paradigms.
  • The 10-10 International system of electrode placement will be used for the scalp EEG recordings with a multichannel high sampling rate amplifier (2 KHz). This will provide standard 10/20 electrode positions (F3, F4, F7, F8, C3, C4, Fz, Cz, T3, T4, T5, T6, P3, P4, O1, O2, and Oz electrodes) which will be initially used to detect the more significant spatiotemporal measurements/phenomena while offering the opportunity to elaborate on the spatial and frequency resolution of our findings at a later stage. Peri-ocular EOG electrode data will also be recorded to detect eye movement related slow wave activity. Investigators will therefore be able to avoid spurious estimates of slow wave activity in the anterior EEG regions.
  • Artefact free epochs within suitable (wakeful no task eyes closed state) will be selected and exported for further quantitative EEG analysis.
  • The exported data will be stored on an external encrypted drive.
  • All the analyses will be performed on custom made in-house software on a high tech computer located within secure offices locked within Dr Sarrigannis's office housed in the department of clinical neurophysiology.

EEG Data analyses • The error reduction ratio-causality method will be used to calculate levels of synchronisation. The standard EEG 10-20 electrodes, including all possible contiguous electrode combinations in pairs of two (e.g. right frontocentral versus parietoccipital) will be used in our pilot exploration to assess the 95% confidence interval levels of synchronisation and determine if they allow robust separation between healthy volunteers and patients with Alzheimer's Disease.

Other Data

  • Qualitative Data collection: Investigators will collect questionnaires on the tolerability of undergoing EEG examination (please find enclosed questionnaire).

Ethical consideration Modern neuro-imaging using MRI is highly sensitive and can detect incidental findings. Our novel EEG analyses also have the potential to detect incidental findings. It is well known that spikes during an inter-ictal EEG have limited clinical significance. However they are seen more frequently in people who have a liability, or lowered threshold, for epilepsy. If any concern is raised about the EEG findings the participant will be reviewed by Dr Blackburn and if appropriate referred onto another neurological colleague. Any incidental findings detected by MRI will be referred to an NHS neurologist through the VPH-DARE@IT project researchers. The Patient Information Sheet and consent will make participants aware of these risks before they take part in the study.

Statistics This pilot project will explore EEG data to investigate the frequency and time domain measurement that would be most appropriate for clinical use. Investigators do not know whether this will involve linear or non-linear interaction and thus we cannot determine which is the most appropriate statistical test. The analysis of similar EEG data sets using parametric methods has explored this in more detail.

Power calculations As this is a proof-of-concept, pilot study to examine the robustness of a novel methodology, it is inappropriate to conduct a formal power calculation. Our initial findings will determine whether our EEG analyses detects functional connectivity correlates of the synchronisation of anterior and posterior networks identified by fMRI BOLD signal during resting state scanning. Investigators will also explore if our data is comparable to previously published quantitative EEG on people with AD. Investigators will explore which measures from our data can discriminate people with Alzheimer's disease from healthy controls. These initial results will give us likely effect sizes and allow us to conduct more accurate power calculations than are presently possible. This will be used to determine the sample size of a larger study of people with dementia.

Conditions
Dementia
Keywords
EEG
Medical subject headings
Dementia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT02426398
Study groupRoleWhat they receive
People with Alzheimer's diseasePeople with Alzheimer's disease
Healthy volunteersHealthy volunteers

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Significant spatiotemporal measurements from EEG

    EEG data analysis

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Apr 2015 (estimated)
  2. Study start19 Nov 2014
  3. Primary completion1 Jun 2028 (estimated)
  4. Study completion1 Jun 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
128 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02426398
Sponsor's protocol ID
STH18419
Status last verified
Oct 2026
First submitted
16 Apr 2015
Last updated
2 Oct 2026
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Dementia, run by Sheffield Teaching Hospitals NHS Foundation Trust at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 2 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Daniel Blackburn, MBChB, PhD (01142222267, d.blackburn@shef.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Significant spatiotemporal measurements from EEG (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in